Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 4/2013

01-07-2013 | Original Article

Osteopontin in bone mineral density of very old Brazilians

Authors: Vinícius C. Souza, Wladimir M. Freitas, Luiz A. Quaglia, Simone N. Santos, Cláudio Córdova, Andrei C. Sposito, Otávio T. Nóbrega

Published in: Journal of Bone and Mineral Metabolism | Issue 4/2013

Login to get access

Abstract

Recent evidence suggests that changes in plasma levels of osteopontin (OPN) may be a promising marker for early diagnosis of bone disorders. We hypothesized that a frequent OPN gene polymorphism may be useful for identifying very old individuals with alterations in plasma OPN levels and consequently at risk of abnormal bone density scores. Men and women (80 years or older) living in the Brazilian Federal District underwent assessments with dual energy X-ray absorptiometry for bone mineral density (BMD) of the femoral neck, femoral head and lumbosacral (L1 to S5) regions. Clinical inspection was performed to assess other physical traits and to exclude co-morbidities (cardiovascular, autoimmunity, infections or neoplastic diseases). Serum concentrations of OPN were determined with an enzyme-linked immunosorbent assay, whereas the A7385G polymorphism (rs1126772) was determined by direct sequencing of a polymerase chain reaction product. Among the two hundred and ten subjects enrolled, no differential scores for bone mineral density could be observed across genotypes, but a greater content of circulating OPN was found among carriers of the A allele (P ≤ 0.05) even after adjustments. Serum OPN levels were negatively correlated with femoral neck density (P = 0.050 for BMD; P = 0.032 for T scores) but not with scores of the other regions investigated. Analyses with the sample dichotomized to age and body mass revealed that this inverse relationship was noticeable only among those aged within the highest and weighing within the lowest intervals. Our findings indicate elevated circulating osteopontin levels in patients with decreased bone mineral density, consistent with a modest contribution of an OPN allelic variation to its expression. Assessing the clinical relevance of our findings demands forthcoming studies.
Literature
1.
go back to reference Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK (2003) Bone loss and bone size after menopause. N Engl J Med 349:327–334PubMedCrossRef Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK (2003) Bone loss and bone size after menopause. N Engl J Med 349:327–334PubMedCrossRef
2.
go back to reference Karlsson MK, Gerdhem P, Ahlborg HG (2005) The prevention of osteoporotic fractures. J Bone Joint Surg Br 87:1320–1327PubMed Karlsson MK, Gerdhem P, Ahlborg HG (2005) The prevention of osteoporotic fractures. J Bone Joint Surg Br 87:1320–1327PubMed
3.
go back to reference Thurner PJ, Chen CG, Ionova-Martin S, Sun L, Harman A, Porter A, Ager JW 3rd, Ritchie RO, Alliston T (2010) Osteopontin deficiency increases bone fragility but preserves bone mass. Bone 46:1564–1573PubMedCrossRef Thurner PJ, Chen CG, Ionova-Martin S, Sun L, Harman A, Porter A, Ager JW 3rd, Ritchie RO, Alliston T (2010) Osteopontin deficiency increases bone fragility but preserves bone mass. Bone 46:1564–1573PubMedCrossRef
4.
go back to reference McCann RM, Colleary G, Geddis C, Clarke SA, Jordan GR, Dickson GR, Marsh D (2008) Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 26:384–393PubMedCrossRef McCann RM, Colleary G, Geddis C, Clarke SA, Jordan GR, Dickson GR, Marsh D (2008) Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 26:384–393PubMedCrossRef
5.
go back to reference Malaval L, Wade-Gueye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, Laroche N, Roux JP, Burt-Pichat B, Duboeuf F, Boivin G, Jurdic P, Lafage-Proust MH, Amedee J, Vico L, Rossant J, Aubin JE (2008) Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 205:1145–1153PubMedCrossRef Malaval L, Wade-Gueye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, Laroche N, Roux JP, Burt-Pichat B, Duboeuf F, Boivin G, Jurdic P, Lafage-Proust MH, Amedee J, Vico L, Rossant J, Aubin JE (2008) Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 205:1145–1153PubMedCrossRef
6.
go back to reference Rittling SR, Denhardt DT (1999) Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 7:103–113PubMedCrossRef Rittling SR, Denhardt DT (1999) Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 7:103–113PubMedCrossRef
7.
go back to reference Scatena M, Liaw L, Giachelli CM (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27:2302–2309PubMedCrossRef Scatena M, Liaw L, Giachelli CM (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27:2302–2309PubMedCrossRef
8.
go back to reference Chen Y, Bal BS, Gorski JP (1992) Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. J Biol Chem 267:24871–24878PubMed Chen Y, Bal BS, Gorski JP (1992) Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. J Biol Chem 267:24871–24878PubMed
9.
go back to reference Hoyer JR, Otvos L Jr, Urge L (1995) Osteopontin in urinary stone formation. Ann N Y Acad Sci 760:257–265PubMedCrossRef Hoyer JR, Otvos L Jr, Urge L (1995) Osteopontin in urinary stone formation. Ann N Y Acad Sci 760:257–265PubMedCrossRef
10.
go back to reference MacNeil RL, Berry J, D’Errico J, Strayhorn C, Piotrowski B, Somerman MJ (1995) Role of two mineral-associated adhesion molecules, osteopontin and bone sialoprotein, during cementogenesis. Connect Tissue Res 33:1–7PubMedCrossRef MacNeil RL, Berry J, D’Errico J, Strayhorn C, Piotrowski B, Somerman MJ (1995) Role of two mineral-associated adhesion molecules, osteopontin and bone sialoprotein, during cementogenesis. Connect Tissue Res 33:1–7PubMedCrossRef
11.
go back to reference Freitas WM, Quaglia LA, Santos SN, Soares AA, Japiassu AV, Boaventura V, Dos Santos Barros E, Cordova C, Nobrega OT, Sposito AC (2011) Association of systemic inflammatory activity with coronary and carotid atherosclerosis in the very elderly. Atherosclerosis 216:212–216PubMedCrossRef Freitas WM, Quaglia LA, Santos SN, Soares AA, Japiassu AV, Boaventura V, Dos Santos Barros E, Cordova C, Nobrega OT, Sposito AC (2011) Association of systemic inflammatory activity with coronary and carotid atherosclerosis in the very elderly. Atherosclerosis 216:212–216PubMedCrossRef
12.
go back to reference Sociedade Brasileira de Cardiologia-SBC, Sociedade Brasileira de Hipertensão-SBH, Sociedade Brasileira de Nefrologia-SBN (2007) V Brazilian Guidelines in Arterial Hypertension. Arq Bras Cardiol 89:e24–e79 Sociedade Brasileira de Cardiologia-SBC, Sociedade Brasileira de Hipertensão-SBH, Sociedade Brasileira de Nefrologia-SBN (2007) V Brazilian Guidelines in Arterial Hypertension. Arq Bras Cardiol 89:e24–e79
13.
go back to reference D’Alfonso S, Barizzone N, Giordano M, Chiocchetti A, Magnani C, Castelli L, Indelicato M, Giacopelli F, Marchini M, Scorza R, Danieli MG, Cappelli M, Migliaresi S, Bigliardo B, Sabbadini MG, Baldissera E, Galeazzi M, Sebastiani GD, Minisola G, Ravazzolo R, Dianzani U, Momigliano-Richiardi P (2005) Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 52:539–547PubMedCrossRef D’Alfonso S, Barizzone N, Giordano M, Chiocchetti A, Magnani C, Castelli L, Indelicato M, Giacopelli F, Marchini M, Scorza R, Danieli MG, Cappelli M, Migliaresi S, Bigliardo B, Sabbadini MG, Baldissera E, Galeazzi M, Sebastiani GD, Minisola G, Ravazzolo R, Dianzani U, Momigliano-Richiardi P (2005) Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 52:539–547PubMedCrossRef
14.
go back to reference Han S, Guthridge JM, Harley IT, Sestak AL, Kim-Howard X, Kaufman KM, Namjou B, Deshmukh H, Bruner G, Espinoza LR, Gilkeson GS, Harley JB, James JA, Nath SK (2008) Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS ONE 3:e0001757PubMedCrossRef Han S, Guthridge JM, Harley IT, Sestak AL, Kim-Howard X, Kaufman KM, Namjou B, Deshmukh H, Bruner G, Espinoza LR, Gilkeson GS, Harley JB, James JA, Nath SK (2008) Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS ONE 3:e0001757PubMedCrossRef
15.
go back to reference Shao JS, Sierra OL, Cohen R, Mecham RP, Kovacs A, Wang J, Distelhorst K, Behrmann A, Halstead LR, Towler DA (2011) Vascular calcification and aortic fibrosis: a bifunctional role for osteopontin in diabetic arteriosclerosis. Arterioscler Thromb Vasc Biol 31:1821–1833PubMedCrossRef Shao JS, Sierra OL, Cohen R, Mecham RP, Kovacs A, Wang J, Distelhorst K, Behrmann A, Halstead LR, Towler DA (2011) Vascular calcification and aortic fibrosis: a bifunctional role for osteopontin in diabetic arteriosclerosis. Arterioscler Thromb Vasc Biol 31:1821–1833PubMedCrossRef
16.
go back to reference Bidder M, Shao JS, Charlton-Kachigian N, Loewy AP, Semenkovich CF, Towler DA (2002) Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J Biol Chem 277:44485–44496PubMedCrossRef Bidder M, Shao JS, Charlton-Kachigian N, Loewy AP, Semenkovich CF, Towler DA (2002) Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J Biol Chem 277:44485–44496PubMedCrossRef
17.
go back to reference Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21:1401–1409PubMedCrossRef Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21:1401–1409PubMedCrossRef
18.
go back to reference Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, Dear AE, Palmer LJ, Norman PE (2007) Association between osteopontin and human abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 27:655–660PubMedCrossRef Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, Dear AE, Palmer LJ, Norman PE (2007) Association between osteopontin and human abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 27:655–660PubMedCrossRef
19.
go back to reference Aryan M, Kepez A, Atalar E, Hazirolan T, Haznedaroglu I, Akata D, Ozer N, Aksoyek S, Ovunc K, Ozmen F (2009) Association of plasma osteopontin levels with coronary calcification evaluated by tomographic coronary calcium scoring. J Bone Miner Metab 27:591–597PubMedCrossRef Aryan M, Kepez A, Atalar E, Hazirolan T, Haznedaroglu I, Akata D, Ozer N, Aksoyek S, Ovunc K, Ozmen F (2009) Association of plasma osteopontin levels with coronary calcification evaluated by tomographic coronary calcium scoring. J Bone Miner Metab 27:591–597PubMedCrossRef
20.
go back to reference Chiang TI, Chang IC, Lee HS, Lee H, Huang CH, Cheng YW (2011) Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment. Osteoporos Int 22:577–585PubMedCrossRef Chiang TI, Chang IC, Lee HS, Lee H, Huang CH, Cheng YW (2011) Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment. Osteoporos Int 22:577–585PubMedCrossRef
21.
go back to reference Yoshitake H, Rittling SR, Denhardt DT, Noda M (1999) Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 96:8156–8160PubMedCrossRef Yoshitake H, Rittling SR, Denhardt DT, Noda M (1999) Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 96:8156–8160PubMedCrossRef
22.
go back to reference Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT (1998) Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13:1101–1111PubMedCrossRef Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT (1998) Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13:1101–1111PubMedCrossRef
23.
go back to reference Pimenta JR, Zuccherato LW, Debes AA, Maselli L, Soares RP, Moura-Neto RS, Rocha J, Bydlowski SP, Pena SD (2006) Color and genomic ancestry in Brazilians: a study with forensic microsatellites. Hum Hered 62:190–195PubMedCrossRef Pimenta JR, Zuccherato LW, Debes AA, Maselli L, Soares RP, Moura-Neto RS, Rocha J, Bydlowski SP, Pena SD (2006) Color and genomic ancestry in Brazilians: a study with forensic microsatellites. Hum Hered 62:190–195PubMedCrossRef
24.
go back to reference Nobrega OT, Faleiros VP, Telles JL (2009) Gerontology in the developing Brazil: achievements and challenges in public policies. Geriatr Gerontol Int 9:135–139PubMedCrossRef Nobrega OT, Faleiros VP, Telles JL (2009) Gerontology in the developing Brazil: achievements and challenges in public policies. Geriatr Gerontol Int 9:135–139PubMedCrossRef
25.
go back to reference Karnikowski M, Cordova C, Oliveira RJ, Karnikowski MG, Nobrega OT (2007) Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian middle-aged and older adults. Sao Paulo Med J 125:333–337PubMedCrossRef Karnikowski M, Cordova C, Oliveira RJ, Karnikowski MG, Nobrega OT (2007) Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian middle-aged and older adults. Sao Paulo Med J 125:333–337PubMedCrossRef
Metadata
Title
Osteopontin in bone mineral density of very old Brazilians
Authors
Vinícius C. Souza
Wladimir M. Freitas
Luiz A. Quaglia
Simone N. Santos
Cláudio Córdova
Andrei C. Sposito
Otávio T. Nóbrega
Publication date
01-07-2013
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 4/2013
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-013-0425-1

Other articles of this Issue 4/2013

Journal of Bone and Mineral Metabolism 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine